News summary

ProBio and Kun Tuo Announce Strategic Collaboration to Deliver Integrated CDMO-CRO Solutions for Advanced Therapies

Source: PR Newswire • Published: 16 Sept 2026, 14:07

Summarized by Masters of Longevity from PR Newswire.

A news article outlining a new alliance between a CDMO and a CRO to offer integrated development, manufacturing, and clinical support for advanced therapies.

ProBio and Kun Tuo Announce Strategic Collaboration to Deliver Integrated CDMO-CRO Solutions for Advanced Therapies
Key Takeaways
  • ProBio and Kun Tuo formed a collaboration to provide integrated CMC, nonclinical, and clinical operations support for advanced therapies.
  • ProBio has supported over 1,000 GMP batches and contributed to more than 90 IND approvals and IIT programs.
  • Kun Tuo, an IQVIA-owned CRO in China, has about 1,000 employees and has supported over 1,400 clinical trials.
Read the full article at PR Newswire

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.